{"task_id": "499ce844d50ce0ca", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 265/464)", "text": "\nYes (dose + interval)\nAntibiotics\n254\nAntibiotics\n\n--- Page 276 ---\nAntibiotics\nMechanism\nGram positive\nGram negative\nAnaerobes Others\nRenal adjustments\nFluoroquinolones\nCiprofloxacin 500 mg PO/400 mg IV BID\nBactericidal, inhibit DNA synthesis through inhibition\nof DNA gyrase and topoisomerase\n+++Pseudo\nAFB\nYes (interval)\nNorfloxacin 400 mg PO BID\n+++\nYes (dose \u0006 interval)\nOfloxacin 200\u2013400 mg PO BID\n++\nAFB\nYes (dose \u0006 interval)\nLevofloxacin 500\u2013750 mg PO/IV daily\n++\n+++\nAFB\nYes (dose \u0006 interval)\nMoxifloxacin 400 mg PO/IV daily\n++\n+++\n++\nAFB\nYes (dose \u0006 interval)\nGemifloxacin 320 mg PO daily\n++\n+++\nAFB\nYes (dose \u0006 interval)\nMacrolides\nAzithromycin 250 mg PO daily\nBacteriostatic, binds to 50S ribosomes\n+\n+H. flu/legion\n++Mycoplasma\nNo\nClarithromycin 250\u2013500 mg PO BID\n+\n+H. flu/legion\nand Chlamydia for\nall macrolides\nYes (dose)\nErythromycin 250\u2013500 mg PO q6\u201312h\n+\n+Legion\nNo\nTetracyclines\nDoxycycline 100 mg PO/IV q12h\nBacteriostatic, binds to 30S ribosomes\n+\n+Chlamydia\nNo\nMinocycline 50\u2013100 mg PO daily\u2013BID\n+\n+\n+Chlamydia\nNo\nTetracycline 500 mg PO QID\n+\n+Chlamydia\nAvoid\nTigecycline 100 mg IV, then 50 mg q12h\n+++MRSA, VRE\n++Acinetobacter\n+Chlamydia\nNo\nSulfa\nSulfamethoxazole/Trimethoprim 1\u20132\nBactericidal, blocks DNA synthesis\n+\n++Steno, +PJP\nYes (interval)\nSS/DS tab PO BID (also available IV)\nClindamycin\nClindamycin 150\u2013450 mg PO QID or\nBacteriostatic, binds to tRNA complex\n++\n+++\nNo\n300\u2013600 mg IV q6\u201312h\nMetronidazole\nH. pylori,\nMetronidazole 500 mg PO/IV q12h\nBactericidal, DNA breakage\nG. vaginalis\n+++C. diff\n++protozoa\nNo\nGlycopeptides\nVancomycin 15 mg/kg IV q12h\nBactericidal, interferes with peptidoglycan\nand RNA synthesis\n+++\nS. epidermidis, MRSA,\nEntero\n++C. diff\nYes (interval)\nOxazolidinones\nLinezolid 600 mg PO/IV q12h\nBactericidal (Strep) and bacteriostatic\n++MRSA, VRE\n+\n++AFB\nNo\n(Staph, entero), binds to 50S ribosomes\nStreptogramins\nQuinupristin/dalfopristin 7.5 mg/kg IV q8h\nInhibits late + early protein synthesis\n++MRSA, VRE\n+\nNo\nvia central line\n(not E. faecalis)\nLipopeptides\nDaptomycin 4\u20136 mg/kg q24h\nBactericidal, disrupts cell membrane\n++MRSA, VRE\n+\nYes (interval)\nAntibiotics (cont\u2019d)\nAntibiotics\n255", "text_length": 2144, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 265/464)", "type": "chunk", "chunk_index": 264, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.611642", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.612303", "status": "complete", "chunks_added": 2}